Payment overview · 2025
General Payments
$744.64
15 reported records · 3 companies
Healthcare provider profile · identity verified
Nina Logvinenko, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FAIR LAWN, NJ · NPI 1275570335
Verified facts
What the public records show
CMS Open Payments records show Nina Logvinenko, M.D. received $744.64 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 49.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $369.70 | 49.6% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $249.96 | 33.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.98 | 16.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $744.64 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $249.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $108.48 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $91.69 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $53.64 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.55 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.55 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 85 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
119 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 511 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 347 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 54 |
| Omeprazole | Omeprazole | 284 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 44 |
| Donepezil Hcl | Donepezil Hcl | 277 | 40 |
| Metformin Hcl | Metformin Hcl | 238 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 225 | 26 |
| Meloxicam | Meloxicam | 202 | 45 |
| Dexlansoprazole Dr | Dexlansoprazole | 171 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 162 | 28 |
| Sertraline Hcl | Sertraline Hcl | 158 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 41 |
| Furosemide | Furosemide | 146 | 29 |
| Simvastatin | Simvastatin | 137 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 39 |
| Azithromycin | Azithromycin | 122 | 92 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 20 |
| Linzess | Linaclotide | 119 | 17 |
| Vascepa | Icosapent Ethyl | 113 | 15 |
| Meclizine Hcl | Meclizine Hcl | 99 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 16 |
| Lisinopril | Lisinopril | 91 | 16 |
| Allopurinol | Allopurinol | 87 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 22 |
| Creon | Lipase/Protease/Amylase | 85 | 18 |
| Eliquis | Apixaban | 82 | 15 |
| Spironolactone | Spironolactone | 76 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 74 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 13 |
| Telmisartan | Telmisartan | 69 | 17 |
| Tradjenta | Linagliptin | 69 | suppressed |
| Pentoxifylline | Pentoxifylline | 67 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 63 | suppressed |
| Carvedilol | Carvedilol | 60 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Gabapentin | Gabapentin | 58 | 21 |
| Ozempic | Semaglutide | 58 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 55 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 22 |
| Valsartan | Valsartan | 49 | suppressed |
| Atenolol | Atenolol | 48 | 14 |
| Januvia | Sitagliptin Phosphate | 47 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 47 | suppressed |
| Glipizide Er | Glipizide | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | 11 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | 11 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Lidocaine | Lidocaine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $744.64 · 15 records | ABBVIE INC. | CREON, EVENITY, LINZESS, QULIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error